Picture of Tarsus Pharmaceuticals logo

TARS — Tarsus Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapFalling Star

Tarsus Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

* Tarsus Pharmaceuticals Inc  TARS.OQ  reported a quarterly
adjusted loss of 61 cents​​ per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of $-1.28.  The mean expectation of
nine analysts for the quarter was for a loss of 97 cents per
share. Wall Street expected results to range from $-1.28 to -82
cents per share.
    * Revenue rose 2,471.8% to $48.12 million from a year ago;
analysts expected $43.44 million. 
    * Tarsus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 61 cents​.
    * The company reported a quarterly loss of $23.42 million.
    * Tarsus Pharmaceuticals Inc shares had risen by 44.6% this
quarter and gained 134.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 4% in
the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is 62.00 
This summary was machine generated from LSEG data November 14 at
04:13 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.97          -0.61          Beat
 Jun. 30 2024      -0.92          -0.88          Beat
 Mar. 31 2024      -1.20          -1.01          Beat
 Dec. 31 2023      -1.36          -1.31          Beat

Recent news on Tarsus Pharmaceuticals

See all news